23 research outputs found
Receptor-Mediated Gonadotropin Action in Ovary
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66088/1/j.1432-1033.1981.tb05481.x.pd
Two alpha-3-d-Galactosyltransferases in Rabbit Stomach Mucosa with Different Acceptor Substrate Specificities
Effects of peptide-YY on the hypothalamic-pituitary-gonadal axis in healthy men
Context Central and peripheral administration of peptide-YY (PYY) has potent anorectic effects, and PYY analogues are under development as anti-obesity treatments. Recent animal data suggest PYY may also influence the reproductive axis, however the effects of PYY on the human reproductive system are unknown. Objective To investigate the effects of PYY administration on the reproductive axis in healthy young men. Design Single-blind, randomised, placebo-controlled crossover study. Setting Clinical Research Facility, Imperial College Healthcare NHS Trust. Participants Eighteen healthy eugonadal men (mean age 24.1±0.9years, mean BMI 22.2±0.4kg/m2). Intervention Eight-hour intravenous infusion of 0.4pmol/kg/min PYY3-36 or rate-matched vehicle infusion. Results The number of LH pulses (mean number of LH pulses/8hours: PYY 4.4±0.3 vs vehicle 4.4±0.4, p>0.99), LH area under the curve (AUC) (PYY 1503±79IU.min/L vs vehicle 1574±86IU.min/L, p=0.36), FSH AUC (PYY 1158±513IU.min/L vs vehicle 1199±476IU.min/L, p=0.49) and testosterone AUC (PYY 10485±684IU.min/L vs vehicle 11133±803IU.min/L, p=0.24) were similar during PYY and vehicle infusions. Conclusions Acute intravenous infusion of 0.4pmol/kg/min PYY does not affect the reproductive axis in healthy men
Ganglioside Biosynthesis in Golgi Apparatus of Rat Liver. Stimulation by Phosphatidylglycerol and Inhibition by Tunicamycin
Cellular and metabolic specificity in the interaction of adhesion proteins with collagen and with cells
Enzymatic Synthesis of Neolactotetraosylceramide by the N-Acetyllactosamine Synthase of Human Serum
Recommended from our members
Galactooligosaccharides (GOS) inhibit Vibrio cholerae toxin binding to its GM1 receptor
It is widely reported that cholera toxin (Ctx) remains a significant cause of gastrointestinal disease globally, particularly in developing countries where access to clean drinking water is at a premium. Vaccines are prohibitively expensive and have shown only short-term protection. Consequently, there is scope for continued development of novel treatment strategies. One example is the use of galactooligosaccharides (GOS) as functional mimics for the cell-surface toxin receptor (GM1). In this study, GOS fractions were fractionated using cation exchange chromatography followed by structural characterization using a combination of hydrophilic interaction liquid chromatography (HILIC) and electrospray ionization mass spectrometry (ESI-MS) such that their molecular weight profiles were known. Each profile was correlated against biological activity measured using a competitive inhibitory GM1-linked ELISA. GOS fractions containing > 5% hexasaccharides (DP6) exhibited > 90% binding, with EC50 values between 29.27 and 56.04 mg/mL. Inhibition by GOS DP6, was dose dependent, with an EC50 value of 5.10 mg/mL (5.15 mu M MW of 990 Da). In removing low molecular weight carbohydrates that do possess prebiotic, nutraceutical, and/or biological properties and concentrating GOS DP5 and/or DP6, Ctx antiadhesive activity per unit of (dry) weight was improved. This could be advantageous in the manufacture of pharmaceutical or nutraceutical formulations for the treatment or prevention of an acute or chronic disease associated with or caused by the adhesion and/or uptake of a Ctx or HLT